Boehringer Ingelheim, Gubra to develop anti-obesity peptide poly-agonists
It will bring together Gubra’s established expertise in the design, synthesis, pharmaceutical characterization and in vivo testing of therapeutic peptides with Boehringer Ingelheim’s expertise in the research and